Comparison of in vitro activity of ertapenem with other carbapenems against extended-spectrum beta-lactamase-producing Escherichia coli and Kleibsella species isolated in a tertiary children's hospital

Bibliography

• Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae-producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2000;6:460-3
   PubMed Web of Science ®Google Scholar
• Rupp M, Fey P. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention, and drug treatment. Drugs 2003;63:353-65
   PubMed Web of Science ®Google Scholar
• Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing enterobacteriaceae in Europe. Eurosurveillance 2008;13:1-11
   Google Scholar
• Colodner R, Raz R. Extended-spectrum beta-lactamases: the end of cephalosporins? Isr Med Assoc J 2005;7:336-8
   PubMed Web of Science ®Google Scholar
• Jacoby G, Munoz-Price L. Mechanisms of disease: the new (beta)-lactamases. N Engl J Med 2005;352:380-91
   PubMed Web of Science ®Google Scholar
• Ramphal R, Ambrose P. Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis 2006;42:S164-72
   PubMed Web of Science ®Google Scholar
• Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother 2003;52:331-44
   PubMed Web of Science ®Google Scholar
• Behera B, Mathur P, Das A, Kapil A. Ertapenem susceptibility of extended spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care centre in India. Singapore Med J 2009;50:628-32
   PubMedGoogle Scholar
• Betriu C, Salso S, Sancez A, Comparative in vitro activity and the inoculum effect of ertapenem against Enterobacteriaceae resistant to extended-spectrum cephalosporins. Int J Antimicrob Agents 2006;28:1-5
   PubMed Web of Science ®Google Scholar
• Livermore D, Oakton K, Carter M, Warner M. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with poteLactamases. Antimicrob Agents Chemother 2001;45:2831-7
   PubMed Web of Science ®Google Scholar
• Mody RM, Erwin PD, Summers AM, Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms. Ann Clin Microbiol Antimicrob 2007;6:6
   PubMedGoogle Scholar
• Clinical and Laboratory Standards Institute (CLSI). Performance standard for antimicrobial susceptibility testing. 16th Informational Supplement. CLSI document M100-S16. CSLI, Wayne, PA; 2006
   Google Scholar
• Devrim I, Gulfidani G, Tavlı V, Dr. Behçet Uz Çocuk Hastanesinde Antibiyotik Kullanımına İlişkin Nokta Prevelans Çalışması. [Point-Prevalence Study Relating to Antibiotic Usage in Dr. Behcet Uz Children Hospital Point-Prevelance Study for Antibiotics]. Çocuk Enf Derg 2009;3:11-13
   Google Scholar
• Leblebicioglu H, Gunaydın M, Esen S, Surveillance of antimicrobial resistance in Gram negative isolates from intensive care units in Turkey: analysis of data from the last 5 years. J Chemother 2002;14:140-6
   PubMed Web of Science ®Google Scholar
• Ozguneş I, Erben N, Kiremitçi A, The prevelance of extended-spectrum beta-lactamase-producing Escheichia coli and Klebsiella pneumoniae in clinical isolates and risk factors. Saudi Med J 2006;27:608-12
   PubMed Web of Science ®Google Scholar
• Isturiz R. Global resistance trends and the potential impact on empirical therapy. Int J Antimicrob Agents 2008;32(Suppl 4):S201-6
   Google Scholar
• Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Med 2006;119:S20-8
   PubMedGoogle Scholar
• Patzer JA, Dzierzanowska D, Turner PJ. Trends in antimicrobial susceptibility of gram-negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme(1997 – 2007). J Antimicrob Chemother 2008;62:369-75
   PubMedGoogle Scholar
• Walther-Rasmussen J, Høiby N. Class A carbapenemases. J Antimicrob Chemother 2007;60:470-82
   PubMed Web of Science ®Google Scholar
• White RL, Kays MB, Friedrich LV, Pseudoresistance of Pseudomonas aeruginosa resulting from degradation 3of imipenem in an automated susceptibility testing system with predried panels. J. Clin. Microbiol 1991;29:398-400
   Google Scholar
• Woodford N, Dallow JWT, Hill RLR, Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory. Int J Antimicrob Agents 2007;29:456-45
   PubMed Web of Science ®Google Scholar
• Leavitt A, Chmelnitsky I, Colodner R, Ertapenem resistance among extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae isolates. J Clin Microbiol 2009;47:969-74
   PubMed Web of Science ®Google Scholar
• Wexler HA. In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother 2004;54(Suppl 2):11-21
   Google Scholar
• Kiremitci A, Dinleyici EC, Erben N, In vitro activity of ertapenem and other carbapenems against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae clinical isolates in a tertiary care center in Turkey. Expert Opin Pharmacother 2008;9:1441-9
   PubMed Web of Science ®Google Scholar